Open AccessTargeted Therapy for Non-Small Cell Lung Cancer
Author(s) -
김정선,
Eun Joo Kang
Publication year - 2020
Publication title -
the korean journal of medicine
Language(s) - English
Resource type - Journals
eISSN - 2289-0769
pISSN - 1738-9364
DOI - 10.3904/kjm.2020.95.2.78
Subject(s) - ros1 , lung cancer , targeted therapy , medicine , clinical trial , carcinogenesis , cancer research , genetic enhancement , gene , oncology , cancer , bioinformatics , biology , adenocarcinoma , genetics
Treatment of progressive non-small cell lung cancer (NSCLC) has advanced remarkably, due in part to the development of targeted therapies. Several gene alterations, including EGFR, ALK, ROS1, and BRAF, play important roles in carcinogenesis. Therefore, many targeted agents focusing these gene alterations have been developed and proving their therapeutic efficacies in many clinical trials. Now we should test these gene mutations and should apply treatments individually and properly to ensure the maximal survival benefit of each patient. In this review, we summarize the target genes and respective therapeutic agents in NSCLC.